Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4739158 | 0.82 | RAB9A (0.59) | NPC1RAB9ALMNAMAPTCYP2C9 | |
| SCHEMBL26125104 | 0.80 | HTT (0.49) | NPC1RAB9ALMNAMAPTADORA2A | |
| SCHEMBL22979854 | 0.78 | ALDH1A1 (0.48) | NPC1RAB9ALMNAMAPTKMT2A | |
| SCHEMBL5528616 | 0.78 | NR3C1 (0.47) | NPC1RAB9ALMNAMAPTCYP2C9 | |
| SCHEMBL23638187 | 0.77 | NPC1 (0.40) | NPC1RAB9ALMNAMAPTCYP2C9 | |
| SCHEMBL2418287 | 0.77 | CA1 (0.44) | NPC1RAB9ALMNAMAPTCYP2C9 | |
| SCHEMBL25060006 | 0.75 | ADORA2A (0.54) | MAPTADORA2AADORA1ALDH1A1ADORA2B | |
| SCHEMBL9510298 | 0.75 | HSD17B10 (0.50) | LMNAMAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL2394925 | 0.75 | TSHR (0.40) | MAPTADORA2AADORA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21965751 | 0.75 | CYP1A2 (0.47) | RAB9ALMNAMAPTADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| EP-1095021-B1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2003-09-17 | — | — | EP | disclosed |
| US-6593343-B2 | Quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2003-07-15 | — | — | US | disclosed |
| EP-1073639-B1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| US-20020173520-A1 | Quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2002-11-21 | — | — | US | disclosed |
| US-20020173519-A1 | Quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2002-11-21 | — | — | US | disclosed |
| EP-1095021-A1 | QUINOLINE DERIVATIVES | Active Biotech AB (SE) | 2001-05-02 | — | — | EP | disclosed |
| EP-1073639-A1 | QUINOLINE DERIVATIVES | Active Biotech AB (SE) | 2001-02-07 | — | — | EP | disclosed |
| US-6133285-A | 1-METHYL-2-OXO-3-N-PHENYL-N-METHYLAMINOCARBONYL-4-HYDROXY-1,2 -DIHYDRO-QUINOLINES; AUTOIMMUNE DISEASE AND PATHOLOGICAL INFLAMMATION, E.G., ASTHMA, ATHEROSCLEROSIS, STROKE AND ALZHEIMER'S DISEASE AND, ESPECIALLY, MULTIPLE SCLEROSIS | ACTIVE BIOTECH AB (SE) | 2000-10-17 | — | — | US | disclosed |
| US-6077851-A | USED FOR TREATMENT OF DISEASES RESULTING FROM AUTOIMMUNITY SUCH AS MULTIPLE SCLEROSIS, INSULIN-DEPENDENT DIABETES MELLITUS, SYSTEMIC LUPUS ERYTHEMATOSUS, RHEUMATOID ARTHRITIS, INFAMMATORY BOWEL DISEASE AND PSORIASIS; LAQUINIMOD AS NEW CHEMICAL ENTITY | ACTIVE BIOTECH AB (SE) | 2000-06-20 | — | — | US | disclosed |
| WO-2000003991-A1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999055678-A1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173520-A1 | Quinoline derivatives | CYP4F3, IRF3, CXCR3 | NPC1 1497/4885RAB9A 2435/4885LMNA 2998/4885 |
| US-20020173519-A1 | Quinoline derivatives | CASP1, NFKBIA, IL1B | NPC1 1686/4885RAB9A 2111/4885LMNA 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.